<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

4 min read

SmartTRAK's Top 12 Blog Posts of 2023

By Thomas Wallick on 1/30/24 1:04 PM

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

  1. Could Reverse Hips Change the Total Hip Game?
    Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement

  2. Three Ortho Robotics Companies to Watch in 2023
    SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.

  3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
    Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.

    Request a Demo of the SmartTRAK Business Intelligence Platform

Continue Reading
1 min read

Biologics in Sports Medicine - Key Takeaways from the 2023 AOSSM Meeting (Part 2)

By Kim French on 9/12/23 9:30 AM

SmartTRAK highlights key takeaways from the 2023 AOSSM Meeting

As the number of patients seeking treatment for musculoskeletal conditions increases, the orthobiologic market continues to grow, resulting in physicians and companies offering more innovative treatment options. At the 2023 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting in Washington, biological healing was a hot topic. In this article, SmartTRAKidentifies the latest market developments and innovations that will drive growth in the market for sports medicine-related orthobiologics.

This article is Part Two in a two-part series highlighting the key takeaways from this meeting. To download and read Part One, click Biologics in Musculoskeletal Medicine.

To download Part Two of the series "Biologics in Musculoskeletal Medicine," by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below.Download the Article

Continue Reading
2 min read

Biologics in Musculoskeletal Medicine

By Kim French on 8/18/23 9:30 AM

SmartTRAK highlights key takeaways from the 2023 Biologic Association Meeting

At the 2023 Annual Meeting in monumental Washington DC, the Biologic Association and the American Society of Orthopaedic Surgeons (AAOS) teamed up with American Orthopaedic Society for Sports Medicine (AOSSM) to spotlight the growing interest in and latest advancements of biologics in musculoskeletal medicine. Taking center stage and garnering attention was the idea of “biological healing” and the use of biologics in various conditions and at different points of a continuum of care.

Not surprisingly, the Biological Association focused more on autologous therapies, cell culturing and the next generation of biologics, while the AOSSM meeting explored the current use and growing trends of traditional orthobiologics in orthopedic applications. This article, which is downloadable here, is part one in a two-part series highlighting key takeaways from the Biologic Association meeting, including:

  • Biologic Association Key Takeaways
  • Rules of Engagement: Regulations and Needed Standards
    • “Same Surgical Procedure Exception” Guidance
    •  Standards for Autologous Orthobiologics
    • Driving Better Patient Outcomes
  • Current Use of Autologous Therapies and Next Generation of Biologics
    • Current Practice
    • Next Generation of Biologics
  • Notable Investigative Technologies

Although several biologics seem promising to treat musculoskeletal conditions, there is still an uphill battle for widespread use. Current challenges include ...

To download "Biologics in Musculoskeletal Medicine," Part One of the series of articles by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below. Look for Part Two in this series, which will cover key takeaways from AOSSM, highlighting the current use of Orthobiologics and growing trends, in the coming weeks.Download the Article

Continue Reading
2 min read

The Market Shines Bright: Q123 US Orthobio Market Recap

By Freddy Buntoum on 6/30/23 10:03 AM

US Orthobio market shines bright for the first quarter of 2023.

The US Orthobiologics (Orthobio) market performed well during the first quarter of 2023 and looks to be on a solid upswing and shining bright with the rebound of elective procedures as drivers to positive momentum. Q123 saw positive growth in all segments of the US Orthobio market, which closed on high notes, with revenue up +8.9% YoY.
 

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Orthobio Market Recap* are:

  • Complete Q123 Orthobio Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Orthobio Companies' News, Revenues, Data, Charts and Market Shares
  • US Bone Replacement – Springing Back Into Light
    • Growth Factors/Peptides
    • DBM and Synthetics
  • US Cartilage Replacement –The Light Continues To Shine Bright
    • Cellular Grafts
    • Osteochondral Grafts
  • US Soft Tissue Replacement – Sunny Days Continue
    • Soft Tissue Patches
    • Tendon Allografts
  • US Meniscus Replacement – Sun is Shining Back on The Market

Despite continued healthcare staffing shortages and economic uncertainties, the US Bone Replacement experienced high single-digit percentage growth in Q123 as it benefited from increased utilization, especially in ...

Read the entire Q123 US Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.Learn More about Subscribing to SmartTRAK

Continue Reading
2 min read

Orthobiologics News: The Buzz from AAOS 2023

By Kim French on 5/16/23 9:30 AM

Company efforts to grow share, reduce costs and increase revenue

This year’s American Academy of Orthopaedic Surgeon’s (AAOS) Annual Meeting was well attended, lively and appeared to be “getting back to normal.” The exhibit hall flowed with curious surgeons, industry symposiums and innovation talks were standing room only; the annual meeting was pulsating with robust information and industry news. Compared to previous years, the Orthobiologics buzz at AAOS 2023 was immense, and this article highlights some of the latest news.
 
Among the topics discussed in the complete Perspective article, which is available for download here, are:
  • Top of Mind: M&A and Workforce Reductions
  • Macroeconomic Headwinds
  • Momentum for Penetrating Larger Addressable Markets
  • Companies that are Shifting Strategies
    • Anika Therapeutics - Anika has been transforming itself from an osteoarthritis (OA) pain management leader with a huge addressable market to a ...
    • Vericel - US Cartilage Replacement Market leader Vericel continues to shape the market landscape and shift how surgeons are treating ...
    • CONMED - In 2021, CONMED accelerated investments to grow its domestic Orthopedic business, including expanding its ...
  • Latest Updates on Pricing and Reimbursement

In summary, this year’s AAOS meeting was energetic, and most of the news and information was positive. SmartTRAK is eager to see the outcomes of the recent acquisitions and activities associated with capturing more market share and ...

To read the complete "The Orthobiologics Buzz at AAOS 2023" article by Kimberly French, GM, Orthobiologics and Regenerative Medicine, just click the button below. Download the Orthobio Buzz AAOS 2023 Article

Continue Reading
2 min read

Sweet Smell of Roses: Q422 & FY22 US Orthobio Market Recap

By Freddy Buntoum on 4/20/23 11:35 AM

Total Orthobio market bouncing back and coming through 2022 smelling like a rose for the 2nd year in a row.

The US Orthobiologics (Orthobio) market performed well during Q4 and for FY22, and the sweet smell of roses seemed to celebrate a rebound to the market, with elective procedure recovery, new product launches, and pull-through from enabling technologies as drivers to growth and positive momentum. Q422 saw growth in all but one segment of the US Orthobio market, which somewhat offset a stronger finish of the quarter and of the year 2022. Nevertheless, Q422 and FY22 closed on high notes.
 

Among the many topics covered in detail in our comprehensive Q422/FY22 OrthoBio Recap* are:

  • Complete Q422 Trauma Market Overview and Highlights
  • SmartTRAK's Expert Market Analysis and Insights
  • All Company News, Revenues, Data, Charts and Shares
  • US Bone Replacement
    • Good Momentum as Spine Rebounds and Products Launch
  • US Cartilage Replacement
    • Procedure Volumes Stabilizing
  • US Soft Tissue Replacement
    • Winter Months More Like a Sunny Day Rose Parade
  • US Meniscus Replacement 
    • Growth Dampened by a Non-Blooming Group of Small Players

In addition to the previously mentioned market growth drivers, and as SmartTRAK highlighted in its latest trends article, “What Lies Ahead for Orthobiologics in 2023 and Beyond”,* other contributing factors of growth in 2022 and indicators of future growth in the US Orthobio market, included a tremendous level of M&As, strategic alliances and investments in new technologies. Overall, the US Orthobio market performed above expectations and ...

Read the entire Q422 Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares.*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Learn More about Subscribing to SmartTRAK

Continue Reading
2 min read

A Glimpse into 2023: Regen Med Trends

By Freddy Buntoum on 3/31/23 4:04 PM

PRP and Adipose Through the Looking Glass

The interest and demand for regenerative medicine for various conditions and injuries have increased exponentially over the last decade. From January 1, 1990 to December 31, 2012, google searches for regenerative medicine totaled 21,600,000. With increased publicity about stem cells and advancements in cell and gene therapies, biomaterials and tissue engineering, google searches increased nearly ten-fold to 212,000,000 from 1/1/13 to 2/27/23.

Is regenerative medicine really the way of the future? In this article, SmartTRAK looks at the macroeconomic environment going into 2023, as well as some of the latest trends, with a special focus on two segments: platelet-rich-plasma (PRP) and adipose tissue.
 
Among the may topics covered in detail in this comprehensive article are:
  • PRP Trends and the Impacts to 2023 and Beyond
    • Headwinds in 2023
    • Trends in PRP Clinical Trials
    • Anticipated 2023 US PRP Market Share Standings
  • Adipose Trends and the Impacts to 2023 and Beyond
    • Adipose tissue therapy gaining interest in the field of sports medicine
    • Patient demand for minimally-invasive solutions
    • Adipose-derived cell therapies for OA and Degenerative Disc Disease
So is regenerative medicine the way of the future? Time will tell, however, SmartTRAK feels that demand and interest by multiple stakeholders, along with recent trends, medical and legal advancements and investments is tipping the scale to ...

To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.Download the Article

Continue Reading
2 min read

2023 US Hernia Matrices Outlook: Recent Trends and Potential Impact

By Doug Devens on 3/10/23 9:41 AM

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

  • Synthetic Matrices Poised for Slow Down
  • Alternatives to Synthetic Matrices Gaining Favor
    • Xenograft Matrices
    • Resorbable Meshes
    • Reinforced Xenograft Matrices
  • Expert Analysis and Conclusions
Continue Reading
2 min read

What Lies Ahead For Orthobiologics in 2023 and Beyond

By Kim French on 3/6/23 9:30 AM

Market Dynamics, Industry Moves and Technology Advancements 

In 2022, the Orthobiologics Market encountered both ups and downs. Though companies are still reporting year-end results, SmartTRAK feels the Orthobiologics Market finished on a high note. The 2022 challenges, such as staffing shortages at healthcare facilities, supply chain constraints and inflation, may cause headwind in 2023, stifling some growth.

Nevertheless, SmartTRAK anticipates the potential downsides will be offset by elective procedures returning to pre-COVID levels, along with progressive, transitional initiatives by select market players that have the potential to reshape certain orthobiologics segment landscapes.

Among the many topics covered in this Market Outlook article are:

  • Reshaping the Competitive Landscape
  • Shifts in the US Bone Replacement Market
  • Advancements in Osteobiologics
  • Shifts in the US Sports Medicine Market
Continue Reading
3 min read

SmartTRAK is Seeking a Senior Analyst: Spine and OrthoBiologics/Regen

By Sharon O'Reilly on 12/6/22 4:08 PM

Do you love keeping up with the latest trends in the Spine and OrthoBiologics/Regen medicine markets? Are you a closet investigative reporter who loves researching and analyzing what’s going on in the market? Are you looking for a position that leverages your industry knowledge, expertise and connections in new ways? If you are a current or former marketing, market research or business development professional who has worked with one of the major orthopedic/spine companies and looking for a career change, we would love to talk with you.

We are looking to strengthen our SmartTRAK Spine and OrthoBiologics/Regen modules with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for someone with Spine and OrthoBiologics/Regen industry experience who is interested in working full-time. Click the button below to learn more and apply. Learn More and Apply

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles